Aileen
Aileen was diagnosed with breast cancer in December 2016 and she underwent surgery followed by a six-treatment course of chemotherapy.
Aileen was diagnosed with breast cancer in December 2016 and she underwent a lumpectomy with a sentinel node biopsy procedure which led to a further excision and a complete armpit clearance of her lymph nodes. Next, she started a six-treatment course of chemotherapy and at the time of the interview she had one more cycle to complete. She was due to have 20 sessions radiotherapy.
Aileen’s involvement with the 100,000 Genome Project started when she met her breast surgeon to talk about her first operation. At this stage she was given the Information Pack to take home to read. She found it very useful to be able to read the information at her own leisure to make sure she understood what the project would involve before committing herself to it. But, describes the information leaflet as very wordy.
During her pre-op assessment, Aileen and her husband also met a research nurse who provided further information before Aileen consented to take part in the project. The nurse went through the consent form in detail and was happy to answer questions. Aileen has two daughters and was interested to find out if the information about her genetic profile would be of benefit to them. She liked the fact that the consent form has separate boxes, each of which has to be initialled and ticked – each containing different instructions, rather than just providing a general signature for everything. At the end of the meeting, she was given a photocopy of her consent form and she also knows that she can change the instructions she consented to if she wishes to do so.
On reflection, the information and invitation to take part in the Genome project happened at a time when lots of other things were going on in Aileen’s life like the impact of diagnosis, treatment plans, appointments and so forth. So at times, she found it all too much. Despite this, after reading the information and understanding the extent of her participation she realised that she didn’t have to do much – apart from giving tissue and blood samples. She saw only benefits and that’s why she decided to signed the consent form. Her only concern was that she doesn’t know which health professional will get her results, whether it will be her GP or consultant.
Aileen feels that Genomic England should update the information leaflet and also publicise their website address more broadly. Aileen didn’t know about the GEN site when she was diagnosed and felt she missed out on another source of information that was easily available. Another request she made to Genomic England was to send a reminder to participants that they are still part of an ongoing project.
Aileen has no concerns about data protection because she knows her samples were anonymised. Besides, she says that medical research has to go through so many ethical hoops to get approval that it is one of the safest ways to have personal information out there. She thinks that data sharing with companies, like the drug companies are necessary to help develop the treatments that are needed.